key: cord-0929308-mai3u5cl
authors: Molnar, Tihamer; Varnai, Reka; Schranz, Daniel; Zavori, Laszlo; Peterfi, Zoltan; Sipos, David; Tőkés-Füzesi, Margit; Illes, Zsolt; Buki, Andras; Csecsei, Peter
title: Severe Fatigue and Memory Impairment Are Associated with Lower Serum Level of Anti-SARS-CoV-2 Antibodies in Patients with Post-COVID Symptoms
date: 2021-09-23
journal: J Clin Med
DOI: 10.3390/jcm10194337
sha: 4037bfb35ac8f36f511cfffd9d7416a6f8696eb6
doc_id: 929308
cord_uid: mai3u5cl

Background: Post-COVID manifestation is defined as persistent symptoms or long-term complications beyond 4 weeks from disease onset. Fatigue and memory impairment are common post-COVID symptoms. We aimed to explore associations between the timeline and severity of post-COVID fatigue and anti-SARS-CoV-2 antibodies. Methods: Fatigue and memory impairment were assessed in a total of 101 post-COVID subjects using the Chalder fatigue scale (CFQ-11) and a visual analogue scale. Using the bimodal scoring system generated from CFQ-11, a score ≥4 was defined as severe fatigue. Serum anti-SARS-CoV-2 spike (anti-S-Ig) and nucleocapsid (anti-NC-Ig) antibodies were examined at two time points: 4–12 weeks after onset of symptoms, and beyond 12 weeks. Results: The serum level of anti-S-Ig was significantly higher in patients with non-severe fatigue compared to those with severe fatigue at 4–12 weeks (p = 0.006) and beyond 12 weeks (p = 0.016). The serum level of anti-NC-Ig remained high in patients with non-severe fatigue at both time points. In contrast, anti-NC-Ig decreased significantly in severe fatigue cases regardless of the elapsed time (4–12 weeks: p = 0.024; beyond 12 weeks: p = 0.005). The incidence of memory impairment was significantly correlated with lower anti-S-Ig levels (−0.359, p < 0.001). Conclusion: The systemic immune response reflected by antibodies to SARS-CoV-2 is strongly correlated with the severity of post-COVID fatigue.

The SARS-CoV-2 pandemic has had a significant impact on national healthcare systems and economies worldwide, and has changed the lives of millions of people [1] . The illness COVID-19, caused by the SARS-CoV-2 virus, can manifest with a wide range of symptoms from asymptomatic or mild cases to moderate and even severe, life-threatening multisystemic disease [2] . Most initial studies focused mainly on the epidemiology, pathology and potential treatment options of the acute illness. As the number of recovered patients grows,

This prospective single-centre cohort study was conducted at the Clinical Center of University of Pécs (UOP), Hungary with close collaboration of general practitioners (GPs) in the operation area of UOP.

Patients presenting with post-COVID symptoms at the GP office were scheduled for a post-COVID outpatient clinic (baseline visit) to assess their suitability (inclusion/exclusion criteria) for the study. In addition, patients were divided into two groups according to how much time had elapsed between the first symptoms of acute SARS-CoV-2 infection and the date of study enrolment (4-12 weeks vs. >12 weeks). This division was made according to the relevant National Institute of Care and Health Excellence (NICE) guideline [9] . After routine safety studies (BP, ECG) and blood sampling, patients completed the Chalder fatigue scale and two groups were formed based on the results (severe fatigue vs. nonsevere fatigue, see Section 2.2). The severity of the acute illness (need for hospitalization vs. home care), symptoms associated with acute disease (0-4 weeks) and post COVID symptoms (>4 weeks) were also recorded. A post-COVID symptom was defined as any complaint that persisted after the index disease or occurred after week 4 and was not present before the time of infection. Laboratory testing and antibody determination were performed by another unit blinded to patients' data. Inclusion criteria were as follows: (i) at least 30 days elapsed between the onset of symptoms and the date of the outpatient visit; (ii) all participants had at least one positive PCR test or a positive antigen test; (iii) symptomatic status at the time of outpatient appointment; and (iv) patients ≥ 18 years old. Exclusion criteria were as follows: (i) pre-existing malignant or active autoimmune disease; (ii) immunosuppressive therapy; (iii) acute coronary syndrome; (iv) vaccination against SARS-CoV-2; and (v) any condition that may interfere with the assessment of fatigue or cognitive state. Safety studies included 12-lead ECG, and routine laboratory tests were performed during baseline visit including white blood cell (WBC) count, red blood cell (RBC) count, haemoglobin level, serum level of creatinine and urea, serum level of thyroid-stimulating hormone (TSH) and high-sensitivity C-reactive protein (hsCRP), highsensitive Troponin-T (hs-Tn-T), D-dimer, lactic acid dehydrogenase (LDH), and routine urine laboratory testing.

The Chalder fatigue scale (CFQ-11) was used to assess fatigue [11] . An English version of this validated score was translated by an official translation agency into Hungarian to be used in the study. All patients were asked to complete a questionnaire regarding their general condition in the last 3 days. With the use of the Likert scoring system, a score ranging from 0 to 3 was given. From this a global score could be constructed out of a total of 33. Scores for the subscales of physical (0-21) and psychological (0-12) fatigue were also calculated [12] .

To create a case definition for severe fatigue, a bimodal scoring system was used ranging from 0 to 11 [12, 13] . A score of 0 was given when the selected options were "less than usual" and "no more than usual", while a score of 1 was given when "more than usual" and "much more than usual" were reported. Based on the bimodal scoring system, a score of 4 or more indicated caseness (or severe fatigue) [12, 13] .

The Post-COVID-19 Functional Status (PCFS) Scale was used to assess the general impact of post-COVID symptoms on the everyday life of each patient [14] . Only symptoms present in the 7 days prior to the baseline visit were considered in the assessment of symptoms. The severity of each symptom was rated using a visual analogue scale (VAS) ranging between 0 (no symptoms) to 10 (maximal symptom severity). Patients were asked to rate their three most disturbing symptoms and the sum of these formed the total VAS value indicating the overall severity of predominant symptoms. When a patient reported a decline in thinking abilities (including memory), it was defined as subjective cognitive impairment (SCI) [15] , also known as subjective memory disorder. SCI is used as a catch-all term here.

Peripheral blood was collected and immediately centrifuged at 3500 r/min for 15 min. The supernatant was stored at −80 • C until analysis. Antibodies against SARS-CoV-2 were assessed in the peripheral blood by a fully automated Cobas e801 analyser (Roche Diagnostics). For the quantitative analysis of anti-SARS-CoV-2 spike protein antibodies the Elecsys ® Anti-SARS-CoV-2 S electrochemiluminescence immunoassay (Roche Diagnostics, Basel, Switzerland) was used. The assay uses a recombinant protein representing the receptor-binding domain (RBD) of the S antigen in a double-antigen sandwich assay format, which favours the detection of high-affinity antibodies against SARS-CoV-2. The qualitative detection of antibodies to the nucleocapsid protein was performed with the Elecsys ® Anti-SARS-CoV-2 electrochemiluminescence immunoassay (Roche Diagnostics, Basel, Switzerland). The assay uses a recombinant protein representing the nucleocapsid (N) antigen in a double-antigen sandwich assay format. The antigens within the reagents capture predominantly anti-SARS-CoV-2 IgG immunoglobulins (Igs), but also anti-SARS-CoV-2 IgA and IgM. These tests employ a sandwich reaction that includes both biotinylated and ruthenylated SARS-CoV-2 recombinant nucleocapsid and spike antigens incubated with the sample. The addition of streptavidin-coated microparticles allows the complex to be captured magnetically after binding to the solid phase through a biotin-streptavidin reaction. Electrochemiluminescence emission signals are interpolated to generate test results. Assay results were interpreted as follows: cut-off index <1.0, nonreactive/negative for antinucleocapsid antibodies; and cut-off index <0.8 U/mL for antispike antibodies.

Demographic information and data about the index disease were collected from participants. Further information was obtained from patients' electronic records including the clinically relevant data such as the start of the first symptoms, details of hospitalization, in-and outpatient care, antiviral medication, need for oxygen supplementation, regular medication, tobacco use, and premorbid cognitive state or dementia.

The study was approved by the Hungarian Medical Research Council (IV/2505-3/2021/EKU). All procedures were performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was provided by all participants before enrolment in the present study.

Data were evaluated using SPSS (version 11.5; IBM, Armonk, NY, USA). The Kolmogorov-Smirnov test was applied to check for normality. To analyse demographic and clinical factors, the chi-square test was used for categorical data while the Student's t-test was applied to quantitative values. Non-normally distributed data were presented as median and interquartile range (25th-75th percentiles) and were compared with the use of Mann-Whitney test. Correlation analysis was performed by calculating Spearman's correlation coefficient (rho). The best cut-off values of predictors were determined based on ROC analysis. A p-value < 0.05 was considered statistically significant.

A total of 184 patients were eligible for participation in the study, of whom 118 consented for the outpatient baseline assessment and the collection of blood and urine samples. A total of 17 patients were excluded because they did not fulfil inclusion criteria at baseline visit (see Figure 1 ).

The study was approved by the Hungarian Medical Research Council (IV/2505-3/2021/EKU). All procedures were performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was provided by all participants before enrolment in the present study.

Data were evaluated using SPSS (version 11.5; IBM, Armonk, NY, USA). The Kolmogorov-Smirnov test was applied to check for normality. To analyse demographic and clinical factors, the chi-square test was used for categorical data while the Student's t-test was applied to quantitative values. Non-normally distributed data were presented as median and interquartile range (25th-75th percentiles) and were compared with the use of Mann-Whitney test. Correlation analysis was performed by calculating Spearman's correlation coefficient (rho). The best cut-off values of predictors were determined based on ROC analysis. A p-value < 0.05 was considered statistically significant.

A total of 184 patients were eligible for participation in the study, of whom 118 consented for the outpatient baseline assessment and the collection of blood and urine samples. A total of 17 patients were excluded because they did not fulfil inclusion criteria at baseline visit (see Figure 1 ). Finally, data obtained from 101 patients (home care, n = 62, hospitalized, n = 39) were analysed. Table 1 shows the demographic and clinical characteristics of the cohort according to time elapsed from first symptoms to the date of the baseline visit. The mean (SD) age of enrolled participants was 50 years. All patients had symptoms associated with acute SARS-CoV-2 infection with a median number of symptoms of 6 (IQR: 4-7). At first presentation either in hospital or at the GP office, the most common symptoms related to acute SARS-CoV-2 infection were general weakness (79, 78.2%), fever (71, 70.3%), loss of smell (67, 66.3%), cough (62, 61.4%), muscle pain (56, 55.4%), headache (39, 38 .6%), dyspnoe (34, 33 .7%), diarrhoea (27, 26 .7%), skin ache (25, 24 .8%), joint pain (24, 23.8%), chest pain (20, 19 .8%), sickness (19, 18 .8%) and sore throat (16, 15 .8%). The most common post-COVID symptoms mentioned by patients at the baseline visit were fatigue (68.3%), reduction in physical capacity (63.4%), palpitations (49.5%), sleep disturbances (34.7%) and subjective cognitive impairment (17.8%). The total number (median, IQR) of post-COVID symptoms reported by patients on baseline visit was 5 (2) (3) (4) (5) (6) (7) (8) . Table 2 summarizes patient parameters on baseline divided into two groups based on fatigue scale assessment. 2.6 ± 1.9 5 ± 2.6 <0.001 Table 2 . Cont.

Total CFQ-11 score (mean ± SD) (bimodal scoring) 1.5 ± 1. The categorical variables are presented as frequency (%) and the continuous variables are presented as mean ± standard deviation (SD) or median with interquartile range (IQR). The inter-group differences were assessed using chi-square test, Fisher exact test, Student's t-test or Mann-Whitney U test as appropriate in order to compare differences in those without non-severe fatigue and those with severe fatigue as per the CFQ-11 "caseness" definition for severe fatigue. Abbreviations: N, number; BMI, body mass index; PCFS, Post-COVID Functional Status Scale; CTss, computer tomography severity score; CRP, C-reactive protein; NLR, neutrophile-lymphocyte ratio; IL-6, interleukin-6; VAS, visual analogue scale; CFQ-11, Chalder fatigue scale; COVID, coronavirus disease; SARS, severe acute respiratory syndrome; S-Ig, spike immunoglobulin; NC-Ig, nucleocapsid immunoglobulin. * The sum of the VAS score is given for the three most severe symptoms.

The level of anti-SARS-CoV-2 spike Ig (anti-S-Ig) in the serum of post-COVID patients was higher in symptomatic patients at 4-12 weeks compared to post-COVID patients beyond 12 weeks ( Table 1 ). The serum level of both S-Ig and anti-SARS-CoV-2 nucleocapsid Ig (anti-NC-Ig) were elevated in patients with non-severe fatigue compared to those with severe fatigue ( Table 2 ). The level of serum anti-S-Ig was significantly higher in patients with non-severe fatigue compared to those with severe fatigue in symptomatic patients at 

Serum levels of anti-S-Ig were significantly lower in patients <50 years than in those aged 50 years and above (66.1 U/mL, IQR: 25-171 vs. 189 U/mL, IQR: 124-450, p < 0.001). A correlation was also observed for anti-NC-Ig (41.8 U/mL, IQR: 13-66 vs. 84.9 U/mL, IQR: 25-108, p = 0.028). Significantly higher serum levels of anti-S-Ig were also found in the hospitalized group compared to the non-hospitalized group (67.6 U/mL, IQR: 28-144 vs. 246 U/mL, IQR: 151-473, p < 0.001). In contrast, anti-NC-Ig showed no correlation with hospitalization.

At baseline visit, the incidence of SCI was significantly correlated with lower anti-S-Ig levels (144 U/mL, IQR: 62-324 vs. 26.2 U/mL, IQR: 12-101, p < 0.001). In addition, patients with SCI had a higher CFQ-11 score (20, IQR: 18-22 vs. 15, IQR: 11-19, p < 0.001), were younger (45.7 ± 10 vs. 50.9 ± 12, p = 0.041) and had more symptoms at baseline (7 ± 3 vs. 5 ± 2, p = 0.006) than those without SCI at baseline visit. Sleep disorders (56% vs. 30%, p = 0.04), "brain fog" (27.8% vs. 1.2%, p > 0.001) and depression (27.8% vs. 8.4%, p = 0.021) were also more common among patients with SCI than those without memory problems.

Other variables associated with anti-SARS-CoV-2 antibodies on cross-sectional analysis are depicted in Table 3 . Based on the best cut-off value by a ROC analysis, serum anti-NC-Ig level <43.8 U/mL predicted severe fatigue status in this group of patients with a sensitivity of 83.3% and a specificity of 71.4%.

Serum levels of anti-S-Ig were significantly lower in patients <50 years than in those aged 50 years and above (66.1 U/mL, IQR: 25-171 vs. 189 U/mL, IQR: 124-450, p < 0.001). A correlation was also observed for anti-NC-Ig (41.8 U/mL, IQR: 13-66 vs. 84.9 U/mL, IQR: 25-108, p = 0.028). Significantly higher serum levels of anti-S-Ig were also found in the hospitalized group compared to the non-hospitalized group (67.6 U/mL, IQR: 28-144 vs. 246 U/mL, IQR: 151-473, p < 0.001). In contrast, anti-NC-Ig showed no correlation with hospitalization. Variables associated with severe fatigue status were entered into a binary logistic regression model, where the serum level of anti-S-Ig and total number of symptoms at baseline were independently associated with severe fatigue status at baseline, whereas age, level of anti-NC-Ig, total VAS score and total number of symptoms on admission were not (Table 4 ). Next, a separate statistical analysis was run with median values of anti-S-Ig and anti-NC-Ig as an outcome of interest. Based on binary logistic regression analysis, the total value of CFQ-11 score proved to be an independent predictor of median anti-NC-Ig level, while the total value of CFQ-11 scale and need for hospitalization were independently associated with the median anti-S-Ig level. Table 4 . Results of the binary logistic regression analysis examining associations between anti-SARS-CoV-2 antibody levels, severe fatigue status and demographic/clinical variables. 0.371 § In these binary logistic regression models, serum antibody levels were converted to a binary dependent variable, based on the median value of the sample (0: ≤median, 1: >median). Abbreviations: NC-Ig, nucleocapsid immunoglobulin A + M + G); S-Ig, spike immunoglobulin IgA + IgM + IgG; VAS, visual analogue scale; CFQ-11, Chalder fatigue scale; COVID, coronavirus disease; SARS, severe acute respiratory syndrome. * The sum of the VAS (visual analogue scale) score given for the three most severe symptoms.

In the present study, we examined the association between SARS-CoV-2 antibody levels and data from patients with post-COVID symptoms. Patients were categorized into two groups based on the time elapsed between the first symptoms of acute SARS-CoV-2 infection and the date of study enrolment (4-12 weeks vs. >12 weeks). The most common post-COVID symptoms reported by patients were fatigue, reduction in physical capacity, palpitations, sleep disturbances and subjective cognitive impairment. We found that female sex was more prevalent in both the entire patient population and in those with symptoms of severe fatigue. Similarly, the incidence of post-COVID features has recently been reported to be significantly higher among women [16] . Nevertheless, the literature is inconsistent regarding the female dominance of post-COVID syndrome (PCS). In a large cohort study, sex did not behave as an independent predictor of PCS [17] , but similar to our results, female sex was significantly more common in patients with PCS in another study [18] . In accordance with our findings, female sex was more prevalent in the severely fatigued group [18] . Independently of PCS, previous reports have indicated a marked female dominance in chronic fatigue syndrome, which may also suggest a gender-specific pathophysiological process [19] . Importantly, the most frequent symptom reported in our cohort was fatigue (68%) and both the mean value of total CFQ-11 score and the time course of fatigue in our participants were similar to those observed by other authors [18] . Therefore, our study population was suitable for exploring the relationship between antibody response after SARS-CoV-2 and post-COVID fatigue. Anti-SARS-CoV-2 antibody titres were significantly lower in patients under 50 years of age in our cohort. Our findings are in agreement with other studies showing that older age is associated with higher antibody titres in the plasma [20] [21] [22] . Elderly patients also had significantly higher titres of neutralizing antibodies after COVID-19 and higher serum level of CRP at the time of hospital discharge [23] . We found a significantly higher anti-S-Ig titre in patients requiring hospitalization, while the level of anti-NC-Ig showed no correlation with hospitalization. This finding is also in line with numerous studies examining the relationship between symptomatic status and antibody response to COVID-19 infection [22, [24] [25] [26] [27] . Importantly, our cohort included only symptomatic patients, thus we could only compare antibody levels in patients with mild to moderate symptoms. The difference in levels of anti-S-and anti-NC-Ig shown in the hospitalized group in our cohort is intriguing. A previous quantitative analysis of the binding antibody response to the spike and nucleocapsid proteins found a heterogeneous response, and the authors concluded that antibody titres against NC protein may suggest prior exposure to SARS-CoV-2 or related viruses, but do not necessarily provide evidence for the presence of neutralizing antibodies [28] . In our study, we found that the anti-S-Ig titre was higher in patients recruited between 4 and 12 weeks after the onset of symptoms compared to those enrolled beyond 12 weeks, while the titre of anti-NC-Ig did not follow this pattern. Our findings are consistent with previous studies showing a decrease in antibody titres over time [22, 24, 25, 29] . However, antibody titres were preserved during follow-up, irrespective of the severity of symptoms in another study, and patients still had detectable Ig levels even beyond 75 days [26] . In our study, the elapsed time between symptom onset and study enrolment was not an independent predictor of either anti-S-Ig or anti-NC-Ig levels. A previous study demonstrated that immunoglobulins and neutralizing antibodies against SARS-CoV-1 may persist for 2-3 years in recovering patients despite a declining titre [30] .

Overall, it is difficult to extrapolate the results from previous studies due to their different sensitivity and specificity features. Longitudinal studies are needed, as the pattern of decrease in antibody titre may be influenced by several factors.

The key finding of our study is that significantly lower anti-S-Ig and anti-NC-Ig levels were found in patients with severe fatigue, regardless of the time elapsed from the onset of the disease. Moreover, the value of the CFQ-11 scale was an independent predictor of the NC-Ig titre measured at baseline. It has been proposed that the pro-inflammatory environment during late convalescence (≥90 days after symptom onset) could be important in maintaining long-term SARS-CoV-2-specific neutralising antibody levels [31] . We found that both monocyte and leukocyte counts measured at baseline showed a significant positive correlation with anti-S-Ig titre, while the level of anti-NC-Ig showed a similar association with eosinophil count, suggesting a possible link between antibody level and immune cells. The exact cause of post-COVID fatigue is still unknown, but in many features it shows similarities to other chronic fatigue syndromes (CFSs) [32] . A study examining the relationship between immune function and CFS after infectious mononucleosis found that a subset of patients had undetectable Epstein-Barr nuclear antigen (EBNA) Ig titres and diminished immune response against EBV [33] . Our theoretical consideration is that chronic fatigue may be caused by chronic inflammation, and the lower level of antibodies in patients with severe fatigue indicate an unsatisfactory immune response against the viral pathogen. Based on analogy with other similar syndromes, there are several possible mechanisms that might explain this theory. Presumably, the immune system of some patients is poorly activated, resulting in a decreased production of immunoglobulins, slower viral clearance from infected cells, and thus the maintenance of a prolonged inflammatory state which manifests in chronic fatigue. This can be seen after Q fever, where elevated levels of IFN-gamma, IL-1 and IL-6 may underlie chronic fatigue. Q fever fatigue syndrome (QFS) patients show signs of altered immunity and inflammatory profile compared to asymptomatic Q fever seropositive controls [34] . The expression of mitochondrial-derived peptide (MDP)-coding genes MT-RNR1 (MOTS-c) and MT-RNR2 (humanin) are decreased in CFS, QFS and to a lesser extent in Q fever seropositive controls, resulting in a decreased production of humanin. These peptides might be important in the pathophysiology of both QFS and CFS [35, 36] . Another mechanism which could contribute to the alterations in antibody response against COVID-19 is that the different spike or nucleocapsid variations affect the immune mechanism in a similar way to EBV infection regarding the EBNA variations [33] . A further possibility is that COVID-19-associated changes in the intestinal microbiome could be a possible consequence. In case of Q fever, it has been shown that the Bacteroidetes and Firmicutes abundance are reduced in chronic fatigue syndrome compared to healthy individuals [37] . In COVID-19, an increase in Collinsella spp. has been observed. This bacterium has an important role in the maintenance of chronic inflammation [38] . Given the paucity of evidence available, further studies are needed to clarify the exact mechanism of fatigue after COVID-19 infection.

At baseline, the incidence of SCI was significantly correlated with lower anti-S-Ig levels. In the acute phase of COVID-19, the systemic levels of cytokines are elevated [39] . These cytokines can cross the blood-brain barrier, activate microglia and release IL-1β targeting the postsynaptic receptors of hippocampal neurons [40] . This renders the hippocampus vulnerable to IL-1β, which has been shown to disrupt memory [41] . The other mechanism that is likely to play a role in memory impairment during COVID-19 is the decrease of ACE2-mediated brain-derived neurotrophic factor (BDNF) activity [42] . ACE2 regulates normal brain function by stimulating BDNF activity [43] . Low BDNF levels were associated with cognitive impairment in a human study [44] . These pathologies might persist in the post-COVID period, but their contributions to SCI have not been investigated in our study. Consequently, the observed association between low anti-S-Ig levels and SCI requires further investigation. A recent prospective study reporting a beneficial effect of vaccination on physical and mental composite score supports our observed association between antibody levels and post-COVID symptoms such as SCI [45] . The authors assessed 44 vaccinated participants at 1 month after vaccination and compared them with 22 matched unvaccinated participants, and found that those who had received a vaccine experienced an increase in symptom resolution (23.2% vaccinated vs. 15.4% unvaccinated). The lower level of serum antibodies in patients with severe fatigue may indicate insufficient immune response to the index infection, resulting in persisting symptoms. Considering these findings, we speculate that the pronounced immune response induced by the COVID-19 vaccine may promote and activate the entire immune system to eliminate the remaining viral antigens and lead to the improvement of symptoms.

Our study has some limitations. A relatively small sample size was used, and the single antibody measurement limits our ability to evaluate antibody response in a longitudinal setting. Furthermore, an official translation of the CFQ-11 scale per se does not guarantee cross-cultural adaptation and validity. Although the original English version of the CFQ-11 scale is validated, fatigue is a fairly subjective phenomenon and is difficult to measure. Additionally, no imaging studies were performed at baseline to examine structural abnormalities in patients with post-COVID symptoms. Only humoral immunity was studied in our cohort; we have no information on cellular immunity, although this is an important factor in immunity against SARS-CoV-2. Finally, memory impairment was examined based on self-reported patient complains, and validated neuro-cognitive tests were not included.

The serum level of anti-S-Ig was significantly higher in patients with non-severe fatigue compared to those with severe fatigue both at 4-12 weeks and beyond 12 weeks post-COVID. Similarly, the serum level of anti-NC-Ig remained high in patients with nonsevere fatigue at both time points, whereas in patients with severe fatigue, anti-NC-Ig levels significantly decreased regardless of the elapsed time. In addition, the incidence of self-reported memory impairment was correlated with lower anti-S-Ig levels at baseline. Although the cellular immune response was not investigated here, based on these findings, the strength of systemic immune response reflected by anti-SARS-CoV-2 antibody titres may have an impact on both the severity of post-COVID fatigue and memory impairment. 

COVID-19) Dashboard|WHO Coronavirus (COVID-19) Dashboard with Vaccination Data

An overview of COVID-19

Cardiovascular Manifestations of COVID-19 Infection

A comprehensive review of the impact of COVID-19 on human reproductive biology, assisted reproduction care and pregnancy: A Canadian perspective

SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders

Case Definition for Coronavirus Disease 2019 (COVID-19), as of 3

Public Health Surveillance for COVID-19: Interim Guidance

NICE guideline on long COVID

Long covid-mechanisms, risk factors, and management

Development of a fatigue scale

The Chalder Fatigue Scale (CFQ 11)

Exploring the validity of the Chalder Fatigue scale in chronic fatigue syndrome

The Post-COVID-19 Functional Status scale: A tool to measure functional status over time after COVID-19

Subjective Memory Impairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria

Post-COVID-19 syndrome among symptomatic COVID-19 patients: A prospective cohort study in a tertiary care center of Bangladesh

Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study

Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection

Gender differences in chronic fatigue syndrome

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients

Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in

Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients

Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders

SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike

Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Disappearance of antibodies to SARS-associated coronavirus after recovery

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: A longitudinal study

Chronic fatigue syndrome, the immune system and viral infection

Deficient EBV-specific B-and T-cell response in patients with chronic fatigue syndrome

Cytokine profiles in patients with Q fever fatigue syndrome

A possible role for mitochondrial-derived peptides humanin and MOTS-c in patients with Q fever fatigue syndrome and chronic fatigue syndrome

Multi-omics examination of Q fever fatigue syndrome identifies similarities with chronic fatigue syndrome

Gastrointestinal symptoms associated with COVID-19: Impact on the gut microbiome

Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19

The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19

Distribution of interleukin-1 receptor complex at the synaptic membrane driven by interleukin-1β and NMDA stimulation

TNFα and IL-1β but not IL-18 Suppresses Hippocampal Long-Term Potentiation Directly at the Synapse

Possible Neurological and Mental Outcomes of COVID-19 Infection: A Hypothetical Role of ACE-2\Mas\BDNF Signaling Pathway

Angiotensin converting enzyme 2/Ang-(1-7)/mas axis protects brain from ischemic injury with a tendency of age-dependence

Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer's Disease (AD): A Systematic Review and Meta-Analysis

Are Vaccines Safe in Patients with Long COVID? A Prospective Observational Study

We would like to acknowledge the GPs involved in the recruitment of these patients, and we would like to express our thanks for the work of Attilane Pal, who performed the laboratory sampling and processing very precisely.

The authors declare no conflict of interest.